Leveraging PRISM2 for Biomarker Research
Tempus AI and Daiichi Sankyo Partner for Cancer Discovery
The collaboration uses AI foundation models to optimize patient selection for antibody-drug conjugate clinical trials.
A high-tech laboratory environment with digital screens displaying complex molecular structures and data visualizations used for oncology research.
Photo: Avantgarde News
Tempus AI and Daiichi Sankyo announced a strategic collaboration on March 25, 2026 [1]. The partnership focuses on using multimodal AI foundation models to accelerate biomarker discovery [1][2]. Specifically, the companies aim to optimize patient selection for antibody-drug conjugate (ADC) clinical programs [1][3]. The PRISM2 model will play a central role in this oncology research initiative [1]. By analyzing complex datasets, the AI tools help identify which patients are most likely to respond to specific cancer treatments [2]. This technical integration aims to advance clinical differentiation across Daiichi Sankyo's development portfolio [3].
Editorial notes
Transparency note
Drafted with LLM; human-edited
- AI assisted
- Yes
- Human review
- Yes
- Last updated
Risk assessment
Reviewed for sourcing quality and editorial consistency.
Sources
- 1.↗
biospace.com
https://www.biospace.com/press-releases/tempus-announces-strategic-collaboration-with-daiichi-sankyo-to-advance-ai-driven-biomarker-discovery-and-clinical-differentiation-across-an-adc-clinical-program
- 2.↗
investing.com
https://www.investing.com/news/company-news/tempus-ai-partners-with-daiichi-sankyo-on-cancer-drug-development-93CH-4579865
- 3.↗
marketscreener.com
https://www.marketscreener.com/news/tempus-ai-inc-and-daiichi-sankyo-enter-strategic-collaboration-to-advance-ai-driven-biomarker-disc-ce7e5ed3dd8bf62d
Related stories
View all
Topics
About the author
Avantgarde News Desk covers leveraging prism2 for biomarker research and editorial analysis for Avantgarde News.